Clinical Trial

Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)

Study acronym: SAFE-T-HBV
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 18, 2023 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single center, single arm and open-label study to determine the safety of mRNA modified HBV-TCR redirected T-cells and to analyze the changes in tumor microenvironment caused by these HBV-TCR redirected T-cells in subjects with HBV-related HCC who are not amenable to/failed conventional treatment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-02-08; most recent amendment 2023-11-15.
Status change: Not Yet Recruiting → Recruiting 2022-06-27
Trial Details
NCT Number NCT04745403
Lead Sponsor Lion TCR Pte. Ltd.
Conditions Hepatocellular Carcinoma
Enrollment 10 participants
Start Date 2022-05-20
Primary Completion 2026-07-01 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2023-11-18